Walvax Biotechnology Co.Ltd(300142) : the company’s nine valent HPV vaccine is carrying out phase III clinical preparation

After AI express, investors ask questions on the investor interaction platform: does the company delay the research and development progress of 9-price HPV because of the research and development of covid-19 vaccine? According to the current progress, can the company’s 9-price HPV be listed in 2025?

Walvax Biotechnology Co.Ltd(300142) (300142. SZ) said on the investor interaction platform on February 18 that the company’s nine valent HPV vaccine is carrying out phase III clinical preparation, and all work is progressing normally according to the plan.

- Advertisment -